Andrew Hsieh

The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study

Michael H. Davidson, Michael Stevenson, Andrew Hsieh et al. · Journal of clinical lipidology · 2018 · 83 citations · Full text

Life Sciences, Genetics, Internal Medicine +17

Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk

Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch et al. · New England Journal of Medicine · 2025 · 83 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Christie M. Ballantyne, Marc Ditmarsch, John J.P. Kastelein et al. · Journal of clinical lipidology · 2023 · 81 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study

Michael H. Davidson, Michael Stevenson, Andrew Hsieh et al. · Expert Review of Cardiovascular Therapy · 2017 · 54 citations

Medicine, Endocrinology, Internal Medicine +17

The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study

Marcello Arca, Andrew Hsieh, Handrean Soran et al. · Expert Review of Cardiovascular Therapy · 2018 · 48 citations · Full text

Medicine, Internal Medicine, Pharmacology +13